Table 3

Univariate and multivariate Cox regression analysis for overall survival and progression-free survival

Overall survivalProgression-free survival
ParameterUnivariate Cox regressionMultivariate regressionUnivariate regressionMultivariate regression
HR95% CIP valueHR95% CIP valueHR95% CIP valueHR95% CIP value
LIPS signature
 High riskRefRefRefRef
 Low risk0.280.15 to 0.52<0.001***0.270.13 to 0.59<0.001***0.220.12 to 0.39<0.001***0.240.11 to 0.55<0.001***
 Age
 <60 yearsRefRefRefRef
 ≥60 years1.360.77 to 2.410.32.271.14 to 4.530.02*1.130.68 to 1.860.61.580.89 to 2.800.12
 Gender
 MaleRefRefRefRef
 Female10.54 to 1.8611.480.70 to 3.150.3050.770.44 to 1.340.40.990.52 to 1.880.98
Tumor entity
 OthersRefRefRefRef
 HNSCC0.910.54 to 1.550.70.510.21 to 1.250.1421.410.88 to 2.250.10.800.34 to 1.890.618
 NSCLC0.940.56 to 1.590.80.560.23 to 1.400.2160.70.44 to 1.120.10.550.22 to 1.360.20
Brain metastases
 YesRefRefRefRef
 No0.430.24 to 0.790.005**0.560.27 to 1.170.1230.460.26 to 0.800.005**0.850.39 to 1.890.698
PD-L1 TPS
 <1 %/NARefRefRefRef
 1%–49%0.690.39 to 1.240.20.610.31 to 1.220.1620.610.36 to 1.020.060.570.30 to 1.100.093
 50%–100%0.780.43 to 1.410.40.450.21 to 0.950.037*0.890.54 to 1.470.60.630.32 to 1.210.165
Number of previous treatments
 ≥2RefRefRefRef
 0–10.600.34 to 1.080.080.790.39 to 1.590.5080.490.30 to 0.820.005**0.630.36 to 1.110.111
  • *p<0.05, **p<0.01, ***p<0.001.

  • HNSCC, head and neck squamous cell carcinoma; LIPS, liquid immune profile-based signature; NSCLC, non-small cell lung cancer; TPS, tumor proportion score.